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Running title: BMP9 and BMP10 in PAH
Subject descriptor: 17.6 Pulmonary Hypertension: Experimental
Short summary: This manuscript provides new genetic evidence for the association of 
GDF2 mutations with PAH and confirms that these mutations cause impaired BMP9 function 
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4and signaling. Moreover, this study shows for the first time that BMP10 levels are altered in 
PAH and demonstrates biological integration of plasma BMP9 and BMP10 levels. The 
findings provide further justification for the use of therapeutic approaches that enhance 
BMP9 signaling in patients with PAH.
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org.
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5ABSTRACT
Objectives: Recently, rare heterozygous mutations in GDF2 were identified in patients with 
pulmonary arterial hypertension (PAH). GDF2 encodes the circulating bone morphogenetic 
protein, BMP9, which is a ligand for the BMP type 2 receptor (BMPR2). Here we determined 
the functional impact of GDF2 mutations and characterized plasma BMP9 and BMP10 levels 
in patients with idiopathic PAH.
Methods: Missense BMP9 mutant proteins were expressed in vitro and the impact on BMP9 
protein processing and secretion, endothelial signaling and functional activity was assessed. 
Plasma BMP9 and BMP10 levels and activity were assayed in PAH patients with GDF2 
variants, and controls. Levels were also measured in a larger cohort of controls (n=120) and 
idiopathic PAH patients (n=260).
Main Results: We identified novel rare variation at the GDF2 and BMP10 loci, including 
copy number variation. In vitro, BMP9 missense proteins demonstrated impaired cellular 
processing and secretion. PAH patients carrying these mutations exhibited reduced plasma 
levels of BMP9 and reduced BMP activity. Unexpectedly, plasma BMP10 levels were also 
markedly reduced in these individuals. Although overall BMP9 and BMP10 levels did not 
differ between PAH patients and controls, BMP10 levels were lower in PAH females. A 
subset of PAH patients had markedly reduced plasma levels of BMP9 and BMP10 in the 
absence of GDF2 mutations.
Conclusions: Our findings demonstrate that GDF2 mutations result in BMP9 loss-of-
function and are likely causal. These mutations lead to reduced circulating levels of both 
BMP9 and BMP10. These findings support therapeutic strategies to enhance BMP9 or 
BMP10 signaling in PAH.   
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6INTRODUCTION
Pulmonary arterial hypertension (PAH) is a rare but important life-limiting disease that 
typically presents with unexplained breathlessness on exertion (1). The lung pathology is 
characterized by narrowing and obliteration of small pulmonary arteries resulting from 
proliferation of endothelial cells, smooth muscle cells and fibroblasts in the vessel wall (2). 
The resulting elevation in pulmonary vascular resistance leads to severe pulmonary arterial 
hypertension. The pressure-overloaded right ventricle responds initially by hypertrophy, but 
ultimately dilates and fails (3). Average transplant-free 3-year survival remains only 60-70% 
despite existing therapies (3, 4), demanding a search for more effective treatments based on a 
more thorough understanding of the pathobiology.
Human genetic studies have revealed important insights into the pathobiology of 
PAH. Heterozygous mutations in the gene encoding the bone morphogenetic protein type 2 
receptor (BMPR2) are the most common genetic cause of PAH, accounting for 53-86% of 
familial cases and 14-35% of idiopathic cases (5-7). Further cases are accounted for by 
mutations in activin receptor-like kinase 1 (ACVRL1 encoding ALK1), Endoglin (ENG), and 
by mutations in genes encoding signaling intermediaries downstream of BMP receptors, such 
as SMAD9 (7). Additional rare variants have been described in the genes encoding caveolin-1 
(CAV1) (8) and the potassium channel, KCNK3 (9). In a large European cohort study, we 
provided the first evidence for additional causal mutations in GDF2 (which encodes BMP9), 
ATP13A3 (a P5-type ATPase), SOX17 (SRY-Box 17) and AQP1 (aquaporin-1) (10). The 
identification of GDF2 mutations has since been independently replicated (11), accounting 
for 6.7% of idiopathic PAH cases in a Chinese cohort.
It is now known that BMPR2 and ALK1, together with ENG as an accessory receptor, 
form a BMP signaling complex, largely restricted to endothelial cells (12). Of the 12 different 
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7BMPs involved in fundamental and diverse cellular functions, only BMP9 and BMP10 are 
circulating physiological ligands for the BMPR2/ALK1 receptor complex (13). BMP9 is 
expressed primarily in the liver (14, 15), whereas BMP10 is highly expressed in the right 
atrium (15, 16). Recent evidence suggests the presence of circulating BMP9/BMP10 
heterodimers (15). These BMP ligands circulate at physiologically active levels and maintain 
vascular endothelial quiescence (17). Moreover, we previously demonstrated that therapeutic 
administration of BMP9 prevents and reverses PAH in genetic and non-genetic models of 
disease (12). 
Here we sought to determine whether recently identified and novel heterozygous 
mutations in GDF2 cause BMP9 loss-of-function, based on biochemical characterization and 
measurements of BMP9 plasma levels in patients. In addition, we assayed BMP9 and BMP10 
levels in a large PAH cohort and demonstrate that a subset of PAH patients, without 
identified GDF2 mutations, also exhibit reduced circulating BMP9 and BMP10 levels. Some 
of these results have been previously reported in the form of abstracts (18, 19).
METHODS
A cohort of 1048 PAH patients underwent whole genome sequencing, and a case-control rare 
variant analysis was undertaken, as described previously (10). Variants which occurred at a 
frequency of more than 1 in 10000, or were not predicted to disrupt protein structure 
according to in silico prediction analyses, were classified as likely benign (eTable 3). 
We selected 7 missense PAH-associated potentially pathogenic GDF2 variants and 9 
common and/or benign variants for functional comparison. Proteins were expressed as 
prodomain bound BMP9 (Pro:BMP9) as previously reported (10), generating three batches 
per variant. 
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8Plasma levels of BMP9 and pBMP10 were measured in 260 patients with idiopathic 
or heritable PAH, and 120 controls. Patient samples were made available by the UK PAH 
Cohort (www.ipahcohort.com, https://www.ukctg.nihr.ac.uk, Unique Identifier: 
NCT01907295). All patients provided written informed consent and the study was approved 
by the ethics review committee (REC Ref: 13/EE/0203). The control samples were described 
previously (20). 
RESULTS
Identification of GDF2 mutations
Whole genome sequencing identified 7 likely pathogenic missense variants, and 1 frameshift 
variant in GDF2 (n=8) (10). In the present study we searched for additional structural 
variation at the GDF2 locus and identified 2 patients with large deletions, not previously 
described, encompassing the GDF2 locus and several neighboring genes (Table 1, eFigure 
1a). The p.Y351H variant, found in 2 unrelated patients, was not previously reported and is 
predicted to disrupt the hydrophobic core of BMP9 (eFigure 1b). With the additional 4 
carriers identified in this study, we have now identified a total of 12 GDF2 mutation carriers. 
Two patients with GDF2 missense variants (p.M89V and p.Y351H) had a positive family 
history for PAH, with sufficient information available for the M89V variant carrier to 
construct a pedigree, although sequencing data were available only for the proband (eFigure 
1c). 
We compared the demographics and clinical parameters of the GDF2 mutation 
carriers (n=12) with patients harboring heterozygous BMPR2 mutations (n=159) and patients 
with no identified mutation (n=750) (Table 2). GDF2 mutation carriers were similar to PAH 
patients without mutations and showed no features of hereditary hemorrhagic telangiectasia 
(HHT) or vascular anomaly syndromes. GDF2 mutation carriers were significantly older and 
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9had less severe hemodynamics than BMPR2 mutation carriers. Transplant-free survival was 
similar between groups after adjustment for age, sex, and whether cases were incident or 
prevalent. The two patients with large deletions exhibited earlier onset of disease at 19 and 30 
years of age (Table 1). The 19-year-old underwent transplantation after 3 years. Despite the 
deletions affecting several additional genes (eFigure 1), these individuals did not have 
reported co-morbidities. In addition, we searched for potentially deleterious mutations in 
BMP10. Two rare and deleterious missense variants in BMP10 (p.A361E and p.R353C) were 
identified in PAH patients (eTable 4). The individual carrying p.R353C has been reported 
previously (21).
Biochemical characterization of BMP9 variants
BMP9 circulates in a non-covalent complex with its prodomain (Figure 1a) (14). We 
previously reported that missense mutations predicted to be pathogenic in silico cluster at the 
interface of the growth factor and prodomains (10), leading us to hypothesize that they 
disrupt the Pro:BMP9 complex. We expressed BMP9 variants in vitro which were predicted 
to be either: (1) deleterious in the PAH cohort, (2) benign in the PAH cohort, (3) deleterious 
but not exclusive to PAH or, (4) benign and not exclusive to PAH (eTable 3). Measurement 
of the concentration of BMP9 in conditioned media by ELISA demonstrated that the 
secretion of pathogenic variants was markedly reduced (Figure 1b). With the exception of 
P104L (see Discussion), variants predicted to be benign were secreted efficiently. For all 
detectable variants, the measured absorbances paralleled the standard curve, implying that the 
ELISA antibodies cross-reacted fully with these variants and reduced detection was not due 
to epitope change (eFigure 2).
We confirmed the ELISA data by western blotting of conditioned media for the 
growth factor and prodomains of BMP9 (Figure 1c). For pathogenic variants, there was an 
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excess of secreted prodomain compared to growth factor domain, indicating that the 
Pro:BMP9 complex was indeed disrupted (Figure 1d). There was almost no detectable 
secreted growth factor domain for Pro:BMP9-R110W, -E143K, -Y351H and -T413N despite 
quantifiable amounts of secreted prodomain. Western blotting of transfected cell lysates 
revealed that ProBMP9 was efficiently expressed within cells, but compared to Pro:BMP9-
WT, there was a loss of processed species with these pathogenic variants, suggesting reduced 
stability (Figure 1e). 
In addition, we demonstrated a processing defect in the ProBMP9-S320C variant, 
which introduces a substitution immediately adjacent to the furin cleavage site between the 
growth factor and prodomain (eFigure 3a). The ProBMP9-S320C mutation resulted in an 
excess of uncleaved species accumulating in conditioned media (eFigure 3b). Within cell 
lysates, equal amounts of both unprocessed ProBMP9-WT and -S320C were present (eFigure 
3b), indicating a defect during secretion. 
We confirmed that the BMP9 prodomain is glycosylated (eFigure3c-e) and the 
increased molecular weight of the prodomain of the common D218N variant is due to an 
additional de novo glycosylation site, which does not alter function (Figure 2).
Assessment of signaling and functional capacity of BMP9 variants
We undertook a functional assessment of the signaling activity of BMP9 variants in 
conditioned media using hALK1-transfected C2C12 cells, which exhibit a concentration-
response to 10-100 pg/ml of BMP9 (eFigure 4). All secreted growth factor domains had 
potency equivalent to Pro:BMP9-WT (Figure 2a). There was no activity associated with 
conditioned media containing pathogenic variants with negligible detectable growth factor 
domain (Figure 2b, eFigure 5). Similarly, for Pro:BMP9-M89V, activity assays suggested a 
reduced amount of growth factor domain compared to prodomain. The transcriptional activity 
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of BMP9 variants in BOECs (22) was consistent with the ALK1-luciferase experiments 
(Figure 2c,d). 
Finally, we assessed the anti-apoptotic activity of benign and pathogenic variants on 
BOECs by flow-cytometry (Figure 2e)(12). Due to the limited through-put of this approach, 
we screened all the mutants for their capacity to inhibit apoptosis of human pulmonary artery 
endothelial cells (PAECs) by Caspase-GLO® 3/7 assays (Figure 2f,g). These also showed 
most variants possessed anti-apoptotic activity, except for the pathogenic variants which lead 
to a profound loss of secreted growth factor domain, despite the presence of prodomain, 
which had no anti-apoptotic activity. 
PAH patients carrying pathogenic GDF2 alleles exhibit reduced circulating BMP9 and 
BMP10 levels and plasma BMP activity
Using a BMP9 ELISA protocol validated for lack of cross-reactivity (eFigure 6a), spike 
recovery (eFigure 6b-g) and plasma assay diluents (eFigure 6b-h), we measured circulating 
BMP9 plasma levels and activity in patients carrying GDF2 mutations. Plasma from female 
PAH patients who were heterozygous carriers of either benign (Pro:BMP9-G18V, -G74E, -
R82G, -P104L, -I118F, -V154I, -D218N, -G291S, -E297K, -T304M, -R333W) or pathogenic 
(Pro:BMP9-M89V, -A347V, -Y351H, -T413N) alleles, were compared to samples from age-
matched healthy females. Patients carrying pathogenic missense GDF2 variants had 
significantly lower mean plasma BMP9 levels than controls, whereas no significant reduction 
was evident in PAH patients carrying benign variants (Figure 3a). Similarly, PAH patients 
carrying deletions at the GDF2 locus, or the frameshift mutation, exhibited reduced levels of 
plasma BMP9. 
To determine whether reduced BMP9 levels led to reduced plasma activity, we 
exposed HMEC1-BRE luciferase cells, which demonstrate high affinity responses to BMP9 
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(eFigure 7), to plasma (Figure 3b). The BMP activity of plasma followed a similar pattern to 
measured BMP9 concentrations, such that patients with pathogenic missense mutations or 
deletions exhibited reduced activity. Following BMP9 immunoprecipitation in control plasma 
there was reduced activity, confirming that BMP9 is responsible for the majority of plasma 
BMP activity in this assay. 
In addition, we used a pBMP10 ELISA protocol validated for lack of cross-reactivity 
(eFigure 8a), spike recovery and plasma diluents (eFigure 8b-d), to measure circulating 
pBMP10 plasma levels in patients carrying GDF2 mutations. Remarkably, plasma BMP10 
levels were dramatically reduced in BMP9 mutation carriers (Figure 3c). Moreover, plasma 
BMP9 and pBMP10 levels correlated closely, both in controls and in mutation carriers 
(Figure 3d). 
Plasma BMP9 and pBMP10 levels in IPAH and HPAH patients
We next measured BMP9 and pBMP10 levels in 120 control samples and 260 cases of 
heritable or idiopathic PAH (eTable 5). Levels of BMP9 and pBMP10 were significantly 
higher in females than males in both control and PAH groups (Figure 4a). Levels of ligands 
were not associated with age (eFigure 9). No significant differences were observed in the 
plasma levels of BMP9 between PAH patients and controls of the same sex (Figure 4a). 
Although no difference in pBMP10 levels was observed between male controls and male 
PAH patients, pBMP10 levels in females with PAH were significantly lower than control 
females (Figure 4b). When the BMP9 or pBMP10 levels in PAH patients and controls of each 
sex were pooled, PAH patients were overrepresented by two-fold in the lowest quartile of 
either BMP9 or pBMP10 levels, in both males and females (eTable 6). Moreover, a larger 
proportion of male (14/21 for BMP9 and 14/20 for pBMP10) and female (38/56) PAH 
patients shared both BMP9 and pBMP10 levels in their lowest quartiles compared to control 
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males (1/7) and control females (8/77). We confirmed the reduction of BMP9 in these 
samples by ELISA and confirmed reduced activity for inducing ID1 and ID2 transcription in 
endothelial cells (Figure 4c). Consistent with our observation in GDF2 mutation carriers, 
there was a striking correlation between plasma BMP9 and pBMP10 in control subjects 
((Figure 4d), Spearman r = 0.72, 95% CI [0.61;0.80] P<0.0001) and in PAH patients ((Figure 
4e), Spearman r = 0.75, 95% CI [0.68;0.80], P<0.0001).
We hypothesized that a physical association between BMP9 and pBMP10 could 
explain the correlation in measured levels. Immunoprecipitation of BMP9 and BMP10 from 
control samples, followed by ELISA and activity measurements demonstrated that a 
proportion of circulating BMP9 and pBMP10 are physically associated (eFigure 10). Since 
most circulating activity was associated with BMP9, but measured levels of pBMP10 were 
much higher than levels of BMP9, we hypothesized that endogenous pBMP10 is 
predominately unprocessed ProBMP10. Therefore, we compared the immunoreactivity of 
purified ProBMP10 and Pro:BMP10 in the pBMP10 and BMP10 GFD ELISAs (eFigure 
11a,b). This demonstrated that the pBMP10 ELISA detects unprocessed and processed 
pBMP10, whilst the BMP10 GFD ELISA only detects processed Pro:BMP10. In control 
samples, very little endogenous processed Pro:BMP10 was detectable with the BMP10 GFD 
ELISA, despite efficient spike-recovery, which suggests that endogenous pBMP10 is indeed 
unprocessed (eFigure 11c).
Associations between BMP9 and 10 levels and clinical parameters
We compared clinical characteristics between BMP9 (eTable7) and pBMP10 (eTable8) 
tertiles and also undertook correlation analysis for relationships (continuous variables) 
between ligand concentrations and clinical parameters. In PAH patients, BMP9 and pBMP10 
levels were not associated with exercise capacity measured by 6-minute walk test (6MWT) 
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(r=-0.045, 95% CI [-0.22;0.13], p=0.634 and r=0.15, 95% CI [-0.032;0.32], p=0.106 
respectively). Hemodynamics contemporary to the time of sampling were available for 38 
patients but did not show any correlation with BMPs. Of note, BMP9 and pBMP10 levels 
negatively correlated with BMI in PAH cases but not in controls (eFigure 12).
Analysis of clinical blood tests in the PAH cohort revealed that pBMP10 negatively 
correlated with red cell distribution width (RDW) (r= -0.21, 95% CI [-0.35;-0.06], p=0.006) 
and alkaline phosphatase activity (r= -0.16, 95% CI [-0.28;-0.03], p=0.014) and positively 
with albumin concentration (r= 0.32, 95% CI [0.20;0.43], p<0.001), whereas BMP9 levels 
correlated positively with platelet count (r= 0.18, 95% CI [0.05;0.30], p=0.006). Both BMP9 
and pBMP10 correlated negatively with CRP (r= -0.32, 95% CI [-0.45;-0.18], p<0.001; r=-
0.35, 95% CI [-0.47;-0.20], p<0.001 respectively). Binary logistic regression showed that 
plasma pBMP10 concentrations were significantly negatively associated with systemic 
hypertension even after controlling for BMI and sex in the PAH cohort. When pBMP10 
levels were in the lower tertile the log odds ratio of suffering from systemic hypertension 
were, -1.30 95% CI [-2.21;-0.49]. Low pBMP10 concentrations were also predictive of 
diabetes mellitus type 2, but this association disappeared after controlling for BMI and sex. 
Receiver operating characteristics (ROC) curves (eFigure 13) suggested that the cut-off 
values of 6784.7pg/ml (specificity 46.3%, sensitivity 79.2%, AUC 63.8%) and 6180.1pg/ml 
(specificity 51.9%, sensitivity 78.9%, AUC 66%) (data for PAH) were the most 
discriminative to predict systemic hypertension and diabetes mellitus respectively. However, 
the AUC was low for both diseases, indicating a modest predictive capacity. Circulating 
BMP9 levels were not associated with either diabetes mellitus or systemic hypertension. 
During the median follow up of 4.4 years since sampling 48 (19%) PAH patients died, 
resulting in a 1 and 3 years overall survival of 95% and 86%. Neither BMP9 nor pBMP10 
concentrations were predictive of mortality (eFigure 14).  
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DISCUSSION
In this study we provide a detailed functional analysis of rare potentially damaging mutations 
in GDF2 identified in a large European cohort of PAH patients. The majority of mutations 
lead to altered cellular processing of the mature protein and reduced cellular secretion. The 
mutations were associated with reduced circulating levels of BMP9 in these individuals and 
reduced plasma BMP9 activity. These findings support a causal role for these mutations in 
the pathobiology of PAH and provide strong evidence in humans that reduced BMP9 levels 
and activity promote the development of PAH. In addition, the finding of two patients with 
deletions at the GDF2 locus provides new genetic evidence supporting a causal role in PAH. 
Having identified several likely causal missense GDF2 variants based on in silico 
analyses, we went on to functionally characterize these variants. Our observations confirm 
that the Pro:BMP9-M89V, -R110W, -E143K, -S320C, -A347V, -Y351H and -T413N 
mutations exhibit impaired BMP9 processing, secretion or stability. Those mutants predicted 
to be benign functioned normally in vitro, but the common Pro:BMP9-D218N variant, 
predicted to be deleterious in silico, was functionally normal. One exception was Pro:BMP9-
P104L, which was predicted to be deleterious, but functional analysis suggested it is likely to 
be benign. This variant was secreted less efficiently from transfected cells but was not 
disrupted to the same extent as the pathogenic mutants, such that it exhibited normal 
processing and signaling, and the individual carrying this variant had normal plasma levels of 
BMP9. The clustering of pathogenic mutations around the interface between the BMP9 
growth factor and prodomains suggests that destabilization of the BMP9 protein, exemplified 
by the Pro:BMP9-M89V variant, is an important mechanism. The S320C variant, which is 
altered at the prohormone cleavage site, exhibits a processing cleavage defect, confirming a 
recent study of the same mutation (11). These results highlight the importance of careful 
characterization of missense variants before pathogenicity can be confirmed.
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Two recent studies independently validated the original finding of heterozygous 
GDF2 mutations in PAH cohorts (11, 21). A single previous case report had identified a case 
of childhood-onset PAH harboring a homozygous GDF2 truncating mutation (p.Q26X) (23). 
In a Chinese PAH cohort the authors measured plasma BMP9 by ELISA in 19 GDF2 
mutation carriers compared with age- and sex-matched idiopathic PAH patients and healthy 
controls (11). Median plasma BMP9 levels were significantly reduced in idiopathic PAH 
patients and were lowest in patients carrying GDF2 mutations. In our larger analysis of a 
cohort of controls and IPAH patients, we did not observe a significant difference in overall 
BMP9 levels between controls and idiopathic PAH patients. However, we observed that some 
patients with idiopathic PAH (approx. 5.4%) have very low BMP9 levels, unexplained by the 
presence of mutations, with corresponding reduced plasma BMP activity on endothelial cells. 
A recent study found that patients with portopulmonary hypertension have profound 
reductions in plasma BMP9 and that low levels predict the presence of PAH in cirrhosis 
patients (24). Liver disease was specifically excluded in the idiopathic PAH patients recruited 
to our cohort. Taken together, the genetic and non-genetic evidence in humans suggests that 
loss of BMP9 levels, or BMP9 signaling, is an important driver for the development of PAH. 
The observed difference between plasma levels of BMP9 (and pBMP10) in males and 
females is of interest and the underlying mechanism for this difference warrants further study. 
Although higher levels in females superficially conflicts with the observation that idiopathic 
and heritable PAH more commonly affects females, the prognosis of PAH is usually worse in 
male patients.
To our knowledge, ours is the first study to measure plasma levels of BMP10 in PAH 
patients, or indeed in a large cohort of control subjects. Overall, levels of pBMP10 were 
significantly lower in female PAH patients compared with controls. Remarkably, we 
observed a close correlation between the levels of BMP9 and BMP10 in human plasma, 
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suggesting a degree of co-regulation that might be explained, at least in part, by the presence 
of circulating heterodimers of these ligands (15). This is important because GDF2 mutations 
leading to reduced secretion of ligand would be predicted to impact the circulating levels of 
BMP10, as well as BMP9, as observed in this study. We confirmed by immunoprecipitation 
that a proportion BMP9 and pBMP10 are physically associated in the same complex. 
However, we measured levels of pBMP10 by ELISA that were much higher than BMP9, 
which suggests the association is not 1:1. Additionally, only about half of the plasma BMP9 
and pBMP10 were in complex, implying that BMP9:10 heterodimers cannot represent the 
only active form. Intriguingly, we detected appreciable levels of circulating processed 
Pro:BMP9 by ELISA, associated with high activity on cells, but minimal circulating 
processed Pro:BMP10. This suggests that the majority of circulating pBMP10 is unprocessed. 
The potentially important role of BMP10 in PAH is further supported by the finding of two 
individuals with likely pathogenic missense mutations, providing independent validation of 
the previous report of BMP10 mutations from France (21). Unfortunately, plasma was not 
available from these individuals for further analysis.
The human data presented here are important because a recent study in rodents 
suggested that inhibition of BMP9 signaling might be protective against the development of 
pulmonary hypertension (25). Gdf2 knockout mice do not develop spontaneous pulmonary 
hypertension, but the authors found that Gdf2 knockout mice were protected from the 
development of hypoxia-induced pulmonary hypertension. They went on to show that 
inhibition of Bmp9 signaling with a neutralizing anti-BMP9 antibody could also slightly 
prevent the development of pulmonary hypertension during chronic hypoxia. Their results 
directly conflict with another study showing that inhibition of BMP9 and 10 with Fc-ALK1 
exacerbated pulmonary hypertension during chronic hypoxia (24). Taken together, the human 
genetic evidence (10, 11, 21, 23), and data from patients with cirrhosis (24), supports the 
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view that BMP9 and 10 are protective to the pulmonary vascular endothelium, consistent 
with the beneficial effects of therapeutic supplementation of BMP9 in preclinical models 
(12).
Heterozygous GDF2 mutations have been identified previously in a small number of 
patients with a vascular anomaly syndrome resembling hereditary hemorrhagic telangiectasia 
(HHT) (26, 27). The mutations in HHT patients were distinct from those reported in PAH but 
were also predicted to lead to altered cellular processing. The finding of mutations in GDF2 
in both HHT-like syndromes and PAH is perhaps not surprising given that mutations in the 
endothelial receptor for BMP9, ALK1, can also cause either HHT or PAH (28). Of note, none 
of the patients carrying GDF2 mutations in the present study had clinical features of HHT.
In summary, the present study demonstrates that rare heterozygous mutations in 
GDF2 are loss-of-function and likely causal in the pathobiology of PAH. Furthermore, GDF2 
mutations lead to reduced circulating levels of BMP10, as well as BMP9, supporting a degree 
of co-regulation of these ligands. Taken together, these findings further support the central 
role of the BMP9/BMPR2/ALK1 axis in PAH. 
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Nucleotide 
change
c.137_150
delGTGGGC
TGCCTGAG
c.265A>G c.328C>T c.347A>T c.427G>A c.958A>T c.1040C>T c.1051T>C c.1051T>C c.1238C>A del Chr10:
47536678 – 
51819820
del Chr10:
47535814 – 
51823146
Protein 
change
p.Gly46Ala
fsTer21
p.Met89Val
(M89V)
p.Arg110Trp
(R110W)
p.Asp116Val
(D116V)
p.Glu143Lys
(E143K)
p.Ser320Cys
(S320C)
p.Ala347Val
(A347V)
p.Tyr351His
(Y351H)
p.Tyr351His
(Y351H)
p.Thr413Asn
(T413N)
N/A N/A
Consequence Frameshift 
variant
Missense 
variant
Missense 
variant
Missense
variant
Missense 
variant
Missense 
variant
Missense 
variant
Missense 
variant
Missense 
variant
Missense 
variant
Large 
deletion
(4.28Mbp)
Large 
deletion
(4.29Mbp)
Ethnicity European European European European European South-Asian European European European Other European South-
Asian
Age at 
diagnosis
45 53 46 52 45 56 30 73 45 54 19 30
Sex male female female male male male female female female female male female
WHO FC 3 3 2 3 n.d 3 3 3 2 3 4 2
Exercise 
capacity
470
(6WMT)
432
(6MWT)
588
(6MWT)
395
(6MWT)
n.d 403
(6MWT)
220
(Shuttle)
160
(6MWT)
420
(6MWT)
374
(6MWT)
280
(Shuttle)
405
(6MWT)
mPAP 
[mmHg]
46 34 38 55 52 56 53 59 73 50 n.d. 55
PAWP
[mmHg]
16 8 5 9 10 7 n.d 13 9 7 n.d. 8
PVR [WU] 5.8 8.7 6.9 15 8.4 9.4 n.d 11 15 15 n.d. 4.66
CO [L/min] 5 3 4.8 3 5 5.2 4.87 4.1 4.2 2.8 n.d. 10
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Table 1: Gene Changes, Demographics and Pulmonary Hemodynamic Data for PAH Patients Harboring BMP9 Mutations. 
Abbreviations: WHO FC – World Health Organization Functional Class, mPAP – mean pulmonary artery pressure, PVR – pulmonary vascular 
resistance, CO – cardiac output. n.d.- not done. *A relative in the parental generation was affected, but there is not enough information to draw a 
pedigree.        
Family 
history
No Yes No No No No No Yes* No No No No
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BMPR2 
N=159
GDF2 
N=12
No known 
PAH-causal 
mutation 
N=750
p-value N
Sex: ‡ 0.357 921
    female 105 (66%) 7 (58%) 530 (71%)
Age [years] † 39 [32;51] 46 [41;54] 52 [39;66] <0.001 921
Diagnosis: ‡ <0.001 921
    HPAH 51 (32.1%) 2 (16.7%) 7 (0.93%)
    IPAH 108 (67.9%) 10 (83.3%) 743 (99.1%)
WHO class: ‡ . 895
    1 2 (1%) 0 (0%) 15 (2%)
    2 31 (20%) 3 (27%) 140 (19%)
    3 95 (60%) 7 (64%) 482 (66%)
    4 30 (19%) 1 (9%) 89 (12%)
Ethnicity: ‡ 0.328 921
    African 2 (1.26%) 0 (0.00%) 20 (2.67%)
    East-Asian 1 (0.63%) 0 (0.00%) 7 (0.93%)
    European 136 (85.5%) 9 (75.0%) 638 (85.1%)
    Finnish-
European
0 (0.00%) 0 (0.00%) 1 (0.13%)
    Other 14 (8.81%) 1 (8.33%) 38 (5.07%)
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    South-Asian 6 (3.77%) 2 (16.7%) 46 (6.13%)
mPAP [mmHg] † 58 [52;68] 53 [48;56] 52 [43;61] <0.001 877
mPAWP [mmHg] † 9 [7;12] 8 [7;10] 9 [7;12] 0.931 780
PVR[WU] † 14 [11;20] 10 [9;15] 10 [7;14] <0.001 754
CO[L/min] † 3.3 [2.7;4.0] 4.7 [3.5;4.9] 4.0 [3.3;5.1] <0.001 842
NO challenge: ‡ <0.001 373
    non-responder 78 (100%) 4 (100%) 245 (84%)
    vasoresponder 0 (0%) 0 (0%) 46 (16%)
KCO [% pred.] † 82 [74;94] 68 [67;71] 69 [49;84] <0.001 546
Hb [g/l] † 162 [151;173] 140 [132;153] 150 [136;163] <0.001 702
Hct [l/l] † 0.5 [0.5;0.5] 0.4 [0.4;0.4] 0.5 [0.4;0.5] <0.001 575
WBC [x10e9/l] † 9 [7;10] 7 [7;8] 8 [7;10] 0.013 696
Plt [x10e9/l] † 211 [170;251] 225 [208;256] 228 [185;276] 0.079 693
ALP [IU/l] † 75 [62;104] 78 [70;90] 87 [69;113] 0.010 675
Bilirubin [µmol/l] † 18 [12;26] 8 [8;13] 14 [10;22] 0.001 671
WHO FC – World Health Organization Functional Class, mPAP – mean pulmonary artery 
pressure, mPAWP – mean pulmonary artery wedge pressure, PVR – pulmonary vascular 
resistance, NO challenge – Nitric Oxide challenge, KCO – transfer coefficient, Hb- hemoglobin, 
Hct – hematocrit, WBC – white blood cells, Plt – platelets,  ALP – alkaline phosphatase.
Table 2: Clinical characteristics of BMPR2 and GDF2 mutation carriers and patients 
without these mutations. None of the patients showed features of hereditary hemorrhagic 
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telangiectasia. Data are presented as either † median [interquartile range] or ‡ count (%). p- 
values represent the overall comparison across the three patient groups. 
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Figure 1
Figure 1: Characterisation of Expressed BMP9 Mutant Proteins. (a) Schematic of 
different potential species of BMP9. Numbers in brackets correspond to labels on western 
blots. (b) Conditioned media from HEK-EBNA cells expressing Pro:BMP9-WT or missense 
pBMP9 variants were serially diluted and assayed for BMP9 GFD levels by ELISA. Data are 
the mean ± SEM from three independently generated batches of media. Paired Dunnett’s 
multiple comparisons test; *P<0.05, **P<0.01 (c) Western blots of variants in conditioned 
media in non-reducing conditions. The volume loaded was normalized according to 
concentration based on ELISA. Blots are representative of n=3 separate expression batches. 
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(d) The ratio of the band intensities of the growth factor and prodomain for each mutant was 
normalized to WT. † indicates mutants for which GFD concentration was too low to quantify. 
Data are the mean ± SEM from three independently generated batches of media. Paired 
Dunnett’s multiple comparisons test; *P<0.05, **P<0.01 (e) Western blotting of those 
variants not readily detected by ELISA. Cell lysates (30 μg of total protein) and conditioned 
media (3 μl of Pro:BMP9-WT or 45 μl of Pro:BMP9 mutants and media from the empty 
vector control) were loaded. 
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Figure 2
Figure 2: Loss of Activity in Pro:BMP9 Mutants Predicted to be Pathogenic. (a,b) 
C2C12 cells transfected with human ALK1, BRE-luciferase and TK-Renilla plasmids were 
serum-starved followed by treatment with Pro:BMP9 variants (10, 30, 100 pg/ml) for 6h and 
luciferase assay. The Firefly:Renilla luciferase ratios were calculated for each sample and 
data normalized, with cells treated with 100 pg Pro:BMP9-WT designated as 100%, and 
SFM-treated cells SFM as 0%. Data are mean ± SEM from three independently generated 
batches of media. van Elteren test; *Padj<0.05, **Padj<0.01. (c,d) Transcriptional responses 
of BOECs to Pro:BMP9-WT and variants based on quantification of the prodomains. Cells 
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were starved in EBM2/0.1% FBS and then treated with Pro:BMP9-WT and variants (0.5, 1.5, 
5 ng/ml) for 4 h.  The expression of (c) ID1 and (d) BMPR2 mRNA were normalized to B2M 
and are expressed as fold change relative to EBM2/0.1% FBS. Data are mean ± SEM from 
three independently generated batches of media. van Elteren test; **Padj<0.01 ***Padj<0.001. 
(e) BOECs were treated overnight with 5 ng/ml Pro:BMP9-WT or variants (normalized 
according to the amount of prodomain) in EBM2/2% FBS followed by induction of apoptosis 
by addition of TNFɑ and cycloheximide (TNF/CHX) for 3.5 hours. Cells were stained with 
Annexin V-FITC and propidium iodide prior to flow cytometry analysis. Cells were assigned 
as healthy (AV-/PI-), early apoptotic (AV+/PI-) or late apoptotic/necrotic (AV+/PI+). Data are 
the mean ± SEM from three independently generated batches of media. Paired Dunnett’s 
multiple comparisons test; *P<0.05. (f,g) PAECs were starved overnight in EBM2/0.1% FBS 
to induce apoptosis in the presence of Pro:BMP9-WT or variants (0.5, 1 ng/ml). Each BMP9 
treatment was supplemented with conditioned media from HEK-EBNA cells transfected with 
empty vector to equalize the total volume of conditioned media per well (2% v/v for 1 ng/ml, 
1% v/v for 0.5 ng/ml). Apoptosis was measured by Caspase-GLO® 3/7 assays. Data are 
mean ± SEM from for three independent batches of media. van Elteren test; *Padj<0.05
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Figure 3
Figure 3: Loss of active BMP9 in PAH patients carrying putatively pathogenic GDF2 
alleles. (a) BMP9 GFD concentration in EDTA-plasma from diseased, GDF2 heterozygous 
females and healthy age-matched females was measured by ELISA Data are mean ± SEM; 
one-way ANOVA; *P<0.05, **P<0.01. (b) HMEC1-BRE cells quiesced in serum free media 
overnight were treated with 5% plasma for 6 hours before luciferase activity was assessed. 
Data are mean ± SEM; t-test (c) As for a, but for pBMP10 concentration. (d) The 
concentration of pBMP10 plotted against the concentration of BMP9 GFD in EDTA-plasma. 
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Data are mean ± SEM; one-way ANOVA; *P<0.05, **P<0.01. n=8 healthy controls, 11 
benign missense, 4 pathogenic missense and 3 deletion (one of which is an early truncation).
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Figure 4
Figure 4: Plasma BMP9 and pBMP10 levels are not reduced in PAH, but a subset of 
PAH patients exhibit reduced plasma BMP9 and pBMP10 levels. Plasma samples 
collected from control subjects and PAH patients were assayed for (a) BMP9 and (b) 
pBMP10. Data are presented as median ± interquartile ranges (Kruskal-Wallis test; 
**P<0.01, ***P<0.001). (c) hAECs quiesced in 0.1% basal media were incubated with 3% 
EDTA-plasma for 1 hour. Expression of ID mRNA was measured by qPCR and normalized 
to B2M and data expressed as fold-change relative to the EBM2/0.1% FBS control. (mean ± 
SEM; t-test). (d,e) Plasma BMP9 levels were plotted against plasma pBMP10 levels in (d) 
control individuals (n=120) and (e) PAH patients (n=187). Dotted lines represent 25% and 
75% percentiles. Spearman correlation is shown by a solid regression line. 
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Case Ascertainment
The 1048 patients who underwent whole genome sequencing comprised the following subgroups: 908 (86.7%) 
were diagnosed with idiopathic PAH, 58 (5.5%) gave a family history of PAH and 60 (5.7%) gave a history 
of drug exposure associated with PAH. Twenty two cases (2.1%) held a clinical diagnosis of PVOD/PCH. 
All patients were clinically phenotyped at the time of diagnosis. The diagnostic criteria for idiopathic or 
heritable pulmonary arterial hypertension, in accordance with the internationally agreed guidelines were: 
elevated mean pulmonary artery pressure of >25 mm Hg, with pulmonary capillary wedge pressure <15 mm Hg 
and pulmonary vascular resistance [PVR] >3 Wood units at rest. Patents with known associated diseases were 
excluded. The non-PAH patient group (eTable 5) assessed as comparators are described in (1). 
Whole Genome Sequencing and Selection of Mutants
The methodologies for high throughput sequencing and analysis of datasets are described in Graf et al 2018 (1). 
The predicted deleterious impact of amino acid substitutions was analysed in silico using the CADD (2), 
PolyPhen-2 (3), SIFT (4) algorithms. Conservation scores were assessed using the GERP algorithm (5).
Potential PAH-associated pathogenic mutants, confirmed through the in vitro analyses undertaken in this study, 
were defined according to the criteria of: gnomAD frequency <1 in 10000, found in PAH but not other groups 
and predicted by in silico analysis to be damaging. Benign missense variants, confirmed through in vitro 
analysis in this study, were defined as either (a) those predicted to be benign by in silico analyses or (b) variants 
which occurred at a frequency of >1/10000 but predicted to be damaging to the structure. Copy number 
variation analysis for large deletions was assessed as previously described (1).
Clinical phenotyping
Pseudonymised results of routinely performed clinical tests reported in either clinical case notes or electronic 
medical records (EMR) were stored in web-based OpenClinica data capture system (Community edition). 
Twenty-one electronic Clinical Case Report Forms (eCRFs) (Supplementary eTable 1.) distributed across seven 
events (Diagnostic, Continuous data, Follow-up, Epidemiology questionnaire, Suspension, Relatives, Unrelated 
healthy control) were constructed to accommodate routinely available clinical information. To aid data analysis 
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3and improve data quality a number of quality assurance procedures was introduced (automatic and manual data 
checks, sites monitoring visits). Importantly, diagnosis in all patients was verified based on hemodynamic data, 
reported comorbidities, pulmonary function tests results, heart, lung and abdominal organs imaging results and 
clinical blood test data. Portopulmonary hypertension was excluded in accordance with international guidelines. 
The date of diagnosis was the starting point to determine follow-up duration between mutation carriers and 
patients without mutations in known causative genes, date of sampling was a starting point for to determine 
follow-up duration in patients in whom BMP9 and pBMP10 levels were measured. The cut-off date was 
assessed via National Health System Digital Spine portal or equivalent local system. Patients lost to follow-up 
were censored as of the time of the last visit.
ID capture
Demographics
Functional class
Clinical features by history
Clinical features by examination
Risk factors
Hemodynamics
Echocardiography
Electrocardiogram
Lung function
Associated Diseases
Clinical blood tests
Survival
Arterial blood gasses
Imaging 
Exercise performance
Body system
Drug treatment history (PAH)
Drug treatment history (other)
Family history
Epidemiology questionnaire
eTable 1: List of clinical case report forms (eCRFs) for data collection
Statistical analyses of association of GDF2 mutations with clinical phenotypes
The hypothesis tested was to analyse whether PAH patients harboring pathogenic GDF2 mutations exhibited a 
specific phenotype compared to either patients with BMPR2 mutations or patients without a mutation in a 
known PAH gene. Baseline characteristics of the PAH cohort were expressed as numbers and percentages for 
categorical variables, and median (interquartile range) for continuous variables according to data distribution. 
Between groups comparisons were performed using chi-squared test or Kruskal-Wallis rank sum test. The 
association of mutation status with the risk of death was assessed using Cox proportional hazards regression 
models. All model assumptions were checked and met. The Kaplan-Meier method was used to estimate overall 
survival and survival according to mutation status, log-rank test was used for comparisons.
Statistical analyses of association of plasma BMP9 and pBMP10 levels with clinical phenotypes
The hypothesis tested was to analyse if measured plasma levels of BMP9 or pBMP10 in PAH patients were 
associated with other clinical indices of either PAH or co-morbidities. BMP9 and pBMP10 were measured in 
specifically in patients diagnosed with IPAH or HPAH, with exclusion of other Group1 diagnoses and Group 2-
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45 diagnoses. Clinical information from the time of sampling was prospectively collected for PAH patients. 
Categorical data were expressed as numbers and percentages and mean ± standard deviation or median 
(interquartile range) for continuous variables as per data distribution. Normality assumptions were tested using 
the Shapiro-Wilk test. Comparisons between and within groups were performed using parametric and 
nonparametric tests according to data distribution. 
The association of BMP9 and pBMP10 levels with risk of death was assessed using Cox proportional hazard 
regression models. Model assumptions were assessed and satisfied. Overall survival and transplant-free survival 
were calculated from diagnosis and sampling. Where a significant p-value was obtained the analysis was 
adjusted for confounders (sex and age at sampling or age at diagnosis). Ligand levels (dependent variable) were 
expressed as a continuous variable, tertiles and binary variable above and below LOQ.
Binary logistic regression models were fitted to describe the relationship between a binary outcome (diagnosis 
of diabetes mellitus type 2 (DM type 2) and systemic hypertension (HTN)) and BMP9 and pBMP10 levels. 
ROC curves based on a fit of a logistic regression models for both comorbidities were subsequently constructed.
Cell culture
HEK-EBNA cells (ATCC; Manassas, VA) and C2C12 mouse myoblasts (A gift of Professor C. Shanahan, 
King’s College London, UK) were grown in Dulbecco's Modified Eagle Medium (DMEM; Gibco 41965) with 
10% foetal bovine serum (FBS; Invitrogen A384000) and antibiotic-antimycotic (Invitrogen 15420). Pulmonary 
artery endothelial cells (PAECs; Lonza), human aortic endothelial cells (hAECs; Lonza) and Blood outgrowth 
endothelial cells (BOECs) isolated from control subjects (6) were maintained in EBM2 basal media (Lonza CC-
3156) and EGM-2 Singlequot supplements (Lonza CC-4176). For hAECs, 5% FBS was used. For BOECs, 10% 
FBS was used with the heparin omitted. 
Human microvascular endothelial cells (HMEC-1; LGC Standards) stably expressing the BRE-luciferase 
reporter (HMEC-BRE)  were grown in MDCB-131 media (Gibco 10372019) supplemented with 10% FBS, 10 
mM L-Glutamine (Invitrogen 25030-032), 1 mg/ml Hydrocortisone (Sigma H0888), 10 ng/ml EGF (Sigma 
E9644) and antibiotic/antimycotic. In brief, cells were transfected with linearized pGL3-(BRE)2-Luciferase (A 
kind gift from Professor Peter ten Dijke, Leiden University Medical Center, Netherlands)(7) and pSelect-puro 
(Invivogen) followed by selection with puromycin for 10-days. Puromycin-resistant cells were then expanded 
and high affinity BMP9 responsiveness confirmed. For treatments, cells were starved overnight in serum-free 
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5MDCB-131, followed by incubation with plasma samples for 6 hours. Cells were lysed with One-Glo reagent 
(Promega) and luciferase measures in a Promega GloMax® Multi+ luminometer.
BMP9 ELISA
The BMP9 ELISA detected the BMP9 GFD and Pro:BMP9 with equivalence, and did not cross-react with the  
BMP10 GFD or Pro:BMP10 (eFigure S6a). As suggested below, this assay is unlikely to detect ProBMP9.
Spike recovery testing was assessed by preparing serial dilutions of pBMP9-wt (2500 pg/ml, 5000 pg/ml and 
10000 pg/ml) or BMP9-GFD (2500 pg/ml and 5000 pg/ml) in plasma. BMP9 immunoreactivity was measured 
in 1 µl, 5 μl, 10 μl, 15 μl and 25 μl of each serial dilution made to 100 μl with PBS/1% BSA. Four supplements 
were tested: (1) 0.2% GS, (2) 0.2% GS plus 0.5% Triton X-100, (3) 0.2% GS + 4.5 mM EDTA and (4) 0.2% GS 
plus 0.5% Triton X-100 and 4.5 mM EDTA. Of these, Triton X-100 and GS, to reduce plasma matrix 
interactions, increased the recovery of exogenous BMP9, whereas EDTA had no additive effect (eFigure S7b-g). 
For testing of the recovery of endogenous BMP9, immunoreactivity was measured in 5 μl, 10 μl, 15 μl, 25 μl, 50 
μl and 100 μl of plasma, diluted with PBS/1% BSA to a total of 100 μl. To test the effect of 0.2% GS plus 0.5% 
Triton X-100, a 21X concentrated mix was added to samples. Although higher recovery efficiency was achieved 
with 15 µl and 10 µl plasma (eFigure S7b-g), 25 µl was the lowest volume that permitted reliable measurement 
of endogenous BMP9 (eFigure S7h). The optimized ELISA protocol did not detect any non-specific binding in 
samples which had undergone BMP9 immunoprecipitation (eFigure S7h). ELISA quantifications of Pro:BMP9-
WT and pBMP9-S320C compared to western blotting and activity data, suggested that this ELISA only detected 
active Pro:BMP9 and probably does not detect ProBMP9.
The optimized protocol was performed as follows: 
For plasma BMP9 measurements, high binding 96-well ELISA plates (Greiner 655061) were coated with 0.5 
μg/well anti-human BMP9 (R&D Systems MAB3209) in PBS (ThermoFisher BP2438), and incubated 
overnight at 4°C in a humidified chamber. Plates were washed with PBS containing 0.05% Tween 20 (PBS-T), 
followed by blocking with 1% (w/v) bovine serum albumin (BSA, ThermoFisher 12737119) in PBS (PBS/1% 
BSA) for 2 hours at RT. Plasma samples (25μl) were premixed with 75μl PBS/1% BSA containing 0.667% 
Triton X-100 and 0.267% GS to give final concentrations of 0.5% Triton X-100 and 0.2% GS. Recombinant 
human BMP9 standards (4.88-5000 pg/ml) were prepared in the same final concentrations of additives. After 
washing, 0.04 µg/well of anti-human BMP9 detection antibody (R&D Systems BAF3209) was added in 
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1:400 in PBS/1% BSA was added. The ELISA was developed with 1mg/ml 4-Nitrophenyl phosphate disodium 
salt hexahydrate (Sigma N2640) in 1 M Diethanolamine / 0.5 mM MgCl2, pH9.8 and absorbance measured at 
405 nm. Unknown values were extrapolated from the standard curve using a 4-parameter log curve fit. All 
values are presented as the concentration of the BMP9-GFD. Technical duplicates of each sample were assayed, 
and the mean of each duplicate was used as a single data point in statistical analyses.  
For measurement of BMP9 in conditioned media, the above assay was used with 0.2 μg/well of MAB3209 and 
without supplements. Serial dilutions of conditioned media samples were assayed. Detection efficiency curves 
were plotted by using the average estimated neat concentration to infer the concentration after dilution, and the 
slope of these curves was compared to that of the BMP9-GFD standard.
pBMP10 ELISA
This ELISA detects Pro:BMP10 and ProBMP10, therefore we refer to ‘pBMP10’. This ELISA does not detect 
the BMP10 GFD alone, Pro:BMP9 nor BMP9 GFD (eFigure 8a, 11a).
Spike recovery testing was assessed by preparing serial dilutions of Pro:BMP10 (25ng/ml, 50ng/ml and 
100ng/ml) in control plasma followed by measurement of Pro:BMP10 immunoreactivity in 1 μl, 5 μl, 10 μl, 15 
μl and 25 μl of each dilution. Diluent composition and plasma loading volumes were assessed as for the BMP9 
ELISA (eFigure 8).
The optimized protocol was performed as follows: 
For plasma pBMP10 measurements, plates were coated with 0.5 µg/well of anti-human BMP10 (MAB2926; 
R&D Systems) and blocked as above. Plasma samples(30μl) were premixed with 70μl PBS/1% BSA containing 
0.714% Triton X-100, 0.286% GS and 6.42mM EDTA  (final = 0.5% Triton X-100, 0.2% GS and 4.5 mM 
EDTA). Dilutions of the furin-cleaved purified Pro:BMP10 standard (97.65-100000pg/ml GFD equivalent), 
produced as described previously (8), were prepared to give the same final concentrations of additives. After 
washing, anti-human BMP10 propeptide (0.04 µg/well, R&D Systems BAF3956) in 1% BSA, 0.2% goat serum 
was added. Assays were then processed as described for BMP9. All data are presented as the concentration of 
the GFD component.
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This ELISA detects Pro:BMP10 and BMP10 GFD, but not ProBMP10 (eFigure 11b). Spike recovery testing 
was performed by serially diluting Pro:BMP10 (3-50 pg/ml) in control plasma followed by measurement of 
immunoreactivity. Since levels in control plasma were so low, samples were diluted in BioRad ELISA diluent 
(BUF037A) was used to dilute samples, which slightly improved recovery efficiency. 
The protocol was performed as follows:
Capture and detection antibodies were from a commercially available kit (R&D systems DY2926-05) and used 
according to the manufacturer’s instructions. Plasma samples (30μl) were premixed with 70μl BUF037A 
containing 0.714% Triton X-100, 0.286% GS and 6.42mM EDTA (final = 0.5% Triton X-100, 0.2% GS and 4.5 
mM EDTA). Dilutions of the furin-cleaved purified Pro:BMP10 standard (97.65-100000pg/ml GFD equivalent), 
produced as described previously (9) were prepared to give the same final concentrations of additives. Assays 
were then processed as described for BMP9. All data are presented as the concentration of the GFD component.
Plasma samples 
Control EDTA plasma samples (n=120) were collected at Imperial College London from healthy volunteers 
with no known history of pulmonary arterial hypertension. Samples from PAH patients (n=260) were collected 
via the UK National Cohort Study of IPAH and HPAH Biobank. Patients were selected according to a 
confirmed diagnosis of IPAH or HPAH, with exclusion of patients with pulmonary veno-occlusive disease, 
pulmonary capillary hemangiomatosis or if pulmonary capillary wedge pressure was >15. BMP9 levels were 
measured in 260 PAH samples, but pBMP10 measured in 254 of these samples due to insufficient volume of 6 
samples. Whole genome sequencing had been undertaken on all but 2 of these patients, both of whom had 
normal circulating BMP9 and pBMP10 levels.    
Immunoprecipitation 
Protein G conjugated beads (15 μl per sample, ThermoFisher 10004D) were incubated with 20 µl of MAB3209 
(anti-BMP9), MAB2926 (anti-BMP10) or ALK1-Fc (R&D systems 370-AL) in PBS for 1 hour with rotating. 
Beads were washed and incubated with 200 µl of plasma overnight at room-temperature with rotating. Beads 
were then separated with a magnet.
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HMEC-1 cells stably expressing a BMP-Smad response element luciferase reporter (HMEC1-BRE) were 
quiesced in serum free MDCB-131 media overnight, then treated with 5% plasma for 6 hours followed by lysis 
and analysis with One-Glo reagent. Each sample was measured in triplicate, and the mean of each triplicate was 
used as a single data point.
In Vitro production and testing of BMP9 variants
Site-Directed Mutagenesis 
The cloning of the pCEP4-ProBMP9 wild-type (WT) expression vector used for site-directed mutagenesis 
(SDM) has been described previously (9). SDM was carried using PfuTurbo (Agilent 600250) using the 
mutagenesis primers detailed in eTable 1. Sequences were verified by Sanger sequencing (Source Bioscience). 
eTable 2: Site directed mutagenesis primers for human ProBMP9 variants 
Mutation Primer Sequences
p.Gly18Val For: 5’-CTGCTGGCTgtcTCCCTACAGGGGAAG-3’
Rev: 5’-CCCTGTAGGGAgacAGCCAGCAGGGAC-3’
p.Gly74Glu For: 5’-AGCCTTAACCTGAGTgagGTCCCTTCGCA-3’
Rev: 5’-TGCGAAGGGACctcACTCAGGTTAAGGC-3’
p.Met89Val For: 5’-CCGCCGCAGTACgtgATTGACCTGTACAAC-3’
Rev: 5’-GTACAGGTCAATcacGTACTGCGGCGGCT-3’
p.Prol104Leu For: 5’-AAGTCGACTACGctaGCGTCCAACATTGTG-3’
Rev: 5’-GCACAATGTTGGACGCtagCGTAGTCGACTTA-3’
p.Arg110Trp For: 5’-CGTCCAACATTGTGtggAGCTTCAGCAT-3’
Rev: 5’-ATGCTGAAGCTccaCACAATGTTGGAC-3’
p.Ile118Phe For: 5’-TGGAAGATGCCttcTCCATAACTGCCACA-3’
Rev: 5’-GCAGTTATGGAgaaGGCATCTTCCATGCT-3’
p.Glu143Lys For: 5’-CCATTCCTAGGCATaagCAGATCACCAGA-3’
Rev: 5’-GCTCTGGTGATCTGcttATGCCTAGGAATG-3’
p.Val154Ile For: 5’-TGAGCTCCGACTCTATatcTCCTGTCAAAATCACG-3’
Rev: 5’-TTTTGACAGGAgatATAGAGTCGGAGCTCAG-3’
p.Asp218Asn For: 5’-GGGTCCGGTCCaacTCCACCAAGAGCA-3’
Rev: 5’-TTTGCTCTTGGTGGAgttGGACCGGACCC-3’
p.Glu297Lys For: 5’-TCCACAGAGGCAGGTaagAGCAGTCACGA-3’
Rev: 5’-CTCGTGACTGCTcttACCTGCCTCTGTGGA-3’
p.Glu302Val For: 5’-GAGCAGTCACGAGgtgGACACGGATGGC-3’
Rev: 5’-CCATCCGTGTCcacCTCGTGACTGCTCT-3’
p.Ser320Cys For: 5’-GGAAAAGGtgcGCCGGGGCTGGCAGCCACT-3’
Rev: 5’-TGCCAGCCCCGGCgcaCCTTTTCCGCCT-3’
p.Ala347Val For: 5’-AGCTGGATCATTgtaCCCAAGGAGTATGAA-3’
Rev: 5’- GCTTCATACTCCTTGGGtacAATGATCCAG-3’
p.Tyr351His For: 5’-ATTGCACCCAAGGAGcatGAAGCCTACGAGT-3’
Rev: 5’-CTCGTAGGCTTCatgCTCCTTGGGTGCAAT-3’
p.Lys397Arg For: 5’-CTGTGTGCCCACCagaCTGAGCCCCAT-3’
Rev: 5’-AGATGGGGCTCAGtctGGTGGGCACACA-3’
p.Thr413Asn For: 5’-ATGGGGGTGCCCaacCTCAAGTACCATTA-3’
Rev: 5’-TGGTACTTGAGgttGGGCACCCCCATGTC-3’
Page 45 of 72  AJRCCM Articles in Press. Published on 29-October-2019 as 10.1164/rccm.201906-1141OC 
 Copyright © 2019 by the American Thoracic Society 
9Production of non-processable ProBMP10
A non-processable ProBMP10 variant was also produced by mutagenizing the pCEP4-ProBMP10 WT 
expression vector (8). A Q5 site-directed mutagenesis kit (NEB E0554S) was used with For: 5’-
CTCCACTGCCgcAATCAGAAGG-3’ and Rev: 5’- TCATAGATGATGTTTGATCT-3’ primers. The mutation 
results in an amino-acid change within the ProBMP10 furin recognition sequence, R313A. Uncleaved dimeric 
ProBMP10 was purified as described (8).
Production of BMP9 Wild Type and Variant Proteins
Plasmids were transfected into HEK-EBNA cells using polyethylenimine (Polysciences 23966-2) in DMEM 
containing 5% FBS. Cells were changed into serum-free CDCHO expression medium (Gibco 10743029) the 
following day. On day 6, conditioned media were harvested and cleared by centrifugation, with aliquots then 
stored at -80oC. Cell lysates were snap-frozen in SDS-buffer (125 mM Tris pH 7.4, 10% glycerol, 2% SDS) 
supplemented with protease/phosphatase inhibitor (Sigma 11836170001), followed by sonication. For each 
variant, three batches of expression media were generated on separate occasions to ensure reproducibility of our 
observations.  
Immunoblotting
Lysates or culture supernatants were mixed with reducing or non-reducing loading buffer to give a 1X loading 
buffer concentration (62.5mM Tris.HCl pH6.8, 2% SDS, 10% glycerol, 0.0025% bromophenol blue, ± 12.5% β-
mercaptoethanol) and heated at 98°C for 5 min. Samples were immunoblotted and probed for the growth factor 
domain with MAB3209 (1:1000; R&D Systems) for non-reduced samples or sc-514211 (1:1000; Santa Cruz 
Biotechnology) for reduced samples. The prodomain was blotted using AF3879 (1:2500; R&D Systems). Lysate 
blots were re-probed with an antibody toward β-actin (Sigma A5441, clone AC-15). Densitometry was 
performed using FIJI Is Just ImageJ software. 
C2C12-ALK1-BRE-luciferase assay
BMP9 signaling activity was measured as previously described (8). C2C12 cells were seeded in 24 well plates 
and placed in Opti-MEM-1 (31985 Invitrogen). Cells were transfected with pcDNA3-hALK1 (kindly provided 
by Professor Richard C. Trembath, King's College London, UK) or pcDNA3 empty vector, pGL3-(BRE)2-
Luciferase and pRL-TK (Promega E2241) using Lipofectamine 2000 (ThermoFisher 116680). After 4 h, the 
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transfection mixes were removed and growth media added to the cells. After 24 h cells were washed in serum-
free DMEM (SFM) overnight.
Cells were treated in SFM containing pBMP9-WT or variants for 6 h. Technical triplicates of each sample were 
assayed, and the mean of each triplicate was used as a single data point in statistical analyses. The amount of 
conditioned media used was normalized to 10, 30 or 100 pg/ml based on ELISA quantification of the amount of 
BMP9 present. For pathogenic variants where the growth factor domain was highly unstable, quantification was 
based on western blotting of the prodomain. For the empty vector control, a larger volume of conditioned media 
was used than for the pBMP9 mutant with the lowest concentration. Cells were lysed and assayed for Firefly 
and Renilla luciferase activities of using the Dual-Glo Luciferase assay system (Promega E2920) on a GloMax 
luminometer (Promega). The BRE-Luciferase activity was normalized to the Renilla Luciferase activity for each 
sample. The data from each plate were then normalized such that the negative control (SFM) was defined as 0% 
and the positive control (SFM plus 100 pg/ml pBMP9-WT) was assigned a value of 100%. 
Deglycosylation
Protein in conditioned media was deglycosylated using PNGase F according to the manufacturer’s instructions 
(NEB P0704). Approximately 15ng of BMP9-GFD, calculated by ELISA, was deglycosylated and then 
fractionated by SDS-PAGE.
Transcriptional responses
For assessing the transcriptional responses of BOECs to Pro:BMP9-WT and variants, or hAECs to patient 
plasma samples, cells were starved in EBM2 containing 0.1% FBS (EBM2/0.1% FBS) and then treated with 
Pro:BMP9-WT and variants (0.5, 1.5, 5 ng/ml) for 4 hours, or 1% plasma for 1 hour, followed by lysis for RNA 
extraction. Total RNA was extracted using the RNeasy Mini Kit with on-column DNAse digestion (Qiagen). 
cDNA was prepared using a High Capacity Reverse Transcriptase kit (Applied Biosystems). All qPCR reactions 
were prepared with SYBRGreen Jumpstart Taq Readymix (Sigma-Aldrich), ROX reference dye (Invitrogen). 
Custom sense and anti-sense primers for human were: B2M: Forward: 5’-CTCGCGCTACTCTCTCTTTCT-3’, 
Reverse: 5’-CATTCTCTGCTGGATGACGTG-3’; ID1: Forward: 5’-CGAAGTTGGAACCCCGGG-3’, 
Reverse: 5’-CAGGAACGCATGCCGCCTCG-3’; BMPR2: Forward: 
5’CAAATCTGTGAGCCCAACAGTCAA-3’, Reverse: 5’-GAGGAAGAATAATCTGGATAAGGACCAAT-
3’B2M, BMPR2, ID1, were all designed using PrimerBlast (NCBI) (eTable 2). Reactions were amplified on a 
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StepOnePlus Real-Time PCR system (Applied Biosystems). Relative expression of each target gene was 
calculated using the comparative 2-(∆∆Ct) method normalized to B2M. 
Annexin V/PI Apoptosis Assay
Apoptosis inhibition in response to BMP9 was measured as previously described (10). BOECs grown in 6-well 
plates were incubated in EBM2 with 2% FBS (EBM2/2% FBS) overnight alone, or with addition of diluted 
HEK-EBNA conditioned media with 3 ng/ml of BMP9-GFD as calculated by ELISA. After 16 hrs, 
cycloheximide (CHX, Sigma C7698) and TNFα (TNF, R&D Systems 210-TA) were added to the wells to final 
concentrations of 50 μg/ml CHX and 3 ng/ml TNF. After 3-4 hrs, cells were trypsinized and transferred into ice-
cold PBS. Cells were then stained with the Annexin V/PI apoptosis detection kit (BD biosciences 556547) 
according to the manufacturer’s instructions. Staining was analysed with an Accuri flow-cytometer (BD 
biosciences). Data were exported to FlowJo (version 10) for analysis. 
Caspase- GLO® 3/7 Assay
PAECs were grown in 48 well plates. They were then washed and placed into 200 μl EBM2 with 0.1% FBS, or 
EGM2 as a negative control. The EBM2 was supplemented with a mix of conditioned media from HEK-EBNA 
cells transfected with empty vector and variant BMP9 expression vectors such that the cells were exposed to 1 
ng/ml BMP9 and 2% v/v conditioned media, or 0.5 ng/ml BMP9 and 1% v/v conditioned media. Technical 
triplicates of each sample were assayed, and the mean of each triplicate was used as a single datapoint in 
statistical analyses. After overnight treatment, 100 μl of Caspase-GLO® 3/7 reagent (Promega G8091) was 
added and samples analysed on a Promega GloMax® Multi+ luminometer.
Statistical analysis of in vitro data
The hypothesis tested was that some GDF2 mutants may be functionally impaired or poorly secreted. Therefore, 
we generated three independent batches of conditioned media, each batch produced on a different day with a 
fresh transfection. All in vitro experiments were repeated three times, using a different batch for each repeat, 
and statistically compared using matched/paired tests. 
For the C2C12-ALK1-BRE-luciferase, transcriptional response and CaspaseGlo assays, a stratified van Elteren 
test was carried out to compare the response of variant BMP9 to WT BMP9. P values were adjusted to account 
for multiple testing with the Bonferroni method. For measurements of BMP9 secretion into conditioned media, 
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and the ratio of prodomain to growth-factor domain, a paired Dunnett’s multiple comparisons test was used to 
compare the secretion of BMP9 variants to WT BMP9. For analysis of Annexin V/PI apoptosis data, a Freidman 
test was applied with a paired Dunnett’s multiple comparisons test. For analysis of plasma BMP9 measurements 
in ELISA validation and immunprecipitation studies, data were analysed by one-way or two-way ANOVA.  
Data analyses were performed using GraphPad Prism 5 or R and results are shown as meanSEM.   
Page 49 of 72  AJRCCM Articles in Press. Published on 29-October-2019 as 10.1164/rccm.201906-1141OC 
 Copyright © 2019 by the American Thoracic Society 
13
Disease Groups
 hgvsc HGVSp
P
A
H
B
P
D
C
S
V
D
G
E
L
H
C
M
I
C
P
N
P
D
M
P
M
T
P
I
D
S
M
D
S
P
E
E
D
S
R
N
S Sum gnomADfrequency CADD SIFT PolyPhen-2 GERP
c.265A>G p.Met89Val (M89V) 1 0 0 0 0 0 0 0 0 0 0 0 1 0 24.8 D(0) Pr(0.999) 5.37
c.328C>T p.Arg110Trp (R110W) 1 0 0 0 0 0 0 0 0 0 0 0 1 0 35 D(0) Pr(1) 4.35
c.347A>T p.Asp116Val (D116V) 1 0 0 0 0 0 0 0 0 0 0 0 1 0 24.4 D(0.01) Po(0.933) 4.41
c.427G>A p.Glu143Lys (E143K) 1 0 0 0 0 0 0 0 0 0 0 0 1 0 28 D(0) Pr(1) 4.65
c.958A>T p.Ser320Cys (S320C) 1 0 0 0 0 0 0 0 0 0 0 0 1 3.98E-06 23.3 D(0.01) Pr(1) 5.46
c.1040C>T p.Ala347Val (A347V) 1 0 0 0 0 0 0 0 0 0 0 0 1 3.98E-06 23.9 D(0) Pr(0.984) 5.63
c.1051T>C p.Tyr351His (Y351H) 2 0 0 0 0 0 0 0 1 0 0 0 3 1.59E-05 23.8 D(0) Pr(1) 5.63P
A
H
 P
at
ho
ge
ni
c 
M
is
se
ns
e
c.1238C>A p.Thr413Asn (T413N) 1 0 0 0 0 0 0 0 0 0 0 0 1 4.49E-06 26.3 D(0) Pr(1) 5.52
c.53G>T p.Gly18Val (G18V) 1 0 0 0 0 0 0 0 0 0 0 0 1 0 18.47 T(0.19) B(0.036) 4.78
c.221G>A p.Gly74Glu (G74E) 1 1 1 3 0 0 0 0 0 1 0 0 7 2.12E-04 15.93 D(0.04) B(0.395) 4.47
c.244A>G p.Arg82Gly R82G) 2 0 0 0 0 0 0 0 3 0 0 0 5 1.11E-04 24.2 D(0) Po(0.863) 0.39
c.311C>T p.Pro104Leu (P104L) 1 0 0 0 0 0 0 0 0 0 1 0 2 3.19E-05 28.8 D(0) Pr(1) 5.37
c.352A>T p.Ile118Phe (I118F) 2 0 0 0 0 1 0 0 0 0 0 1 4 1.11E-03 0.006 T(0.61) B(0.369) -5.22
c.460G>A p.Val154Ile (V154I) 1 0 0 0 0 0 0 0 0 0 0 0 1 3.98E-06 8.365 T(0.54) B(0.011) -2.13
c.652G>A p.Asp218Asn (D218N) 3 4 2 8 0 4 0 0 0 7 7 2 37 2.51E-03 24.4 D(0.04) Pr(0.999) 5.59
c.871G>A p.Gly291Ser (G291S) 1 0 0 2 1 0 0 0 0 0 0 0 4 7.07E-05 0.002 T(0.53) B(0.007) -7.65
c.889G>A p.Glu297Lys (E297K) 1 0 0 0 0 0 0 0 0 0 0 0 1 1.59E-05 5.909 T(0.13) B(0.005) 4.11
c.905A>T p.Glu302Val (E302V) 2 0 0 0 0 0 0 0 0 0 0 0 2 0 5.967 T(0.18) Po(0.698) 1.47
c.911C>T p.Thr304Met (T304M) 1 0 0 0 2 0 3 1 0 0 3 2 14 1.67E-03 0.007 T(0.12) B(0036) -5.33
c.997C>T p.Arg333Trp (R333W) 1 0 0 0 0 0 0 0 2 0 0 0 3 4.07E-04 6.425 T(0.08) B(0.024) -0.216
Be
ni
gn
 M
iss
en
se
c.1190A>G p.Lys397Arg (K397R) 0 0 0 1 0 0 0 0 0 0 0 0 1 2.50E-04 25.8 D(0.01) Pr(0.997) 5.52
eTable 3: Summary of GDF2 missense mutations for BMP9 variants assessed functionally in this study. 
Bold - variants defined in this study as PAH pathogenic missense, Italics – variants defined as benign missense. Disease Groups: PAH - idiopathic and heritable pulmonary 
arterial hypertension; BPD - bleeding, thrombotic and platelet disorders, CSVD - cerebral small vessel disease, GEL – 100,000 Genomes Study UK,  HCM – hypertrophic 
cardiomyopathy, ICP - intrahepatic cholecystis of pregnancy, NPD – neuropathic pain disorders, MPMT – multiple primary malignant tumours, PID - primary immune 
disorders, SMD - stem cell and myeloid disorders, SPEED - specialist pathology: evaluating exomes in diagnostics, SRNS - steroid resistant nephrotic syndrome, SIFT: D – 
Deleterious, T – Tolerated.  PolyPhen-2: Pr – probably damaging, Po – possibly damaging, B = benign. Dark grey cell for D218N: 3 homozygote patients identified. 
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Variable E001250 E010850
Gene changes
Nucleotide change c.1082C>A c.1057C>T
Protein change p.Ala361Glu (A361E) p.Arg353Cys (R353C)
Consequence Missense variant Missense variant
CADD 25.7 28.2
SIFT deleterious deleterious
PolyPhen-2 Probably damaging Probably damaging
GERP 6.07 6.07
Demographics and functional status
Age at diagnosis 72 28
Sex male female
Ethnic category White & Black Caribbean Other White
Genetic race African Other
WHO class 3 4
6MWD [m] 340 215
Hemodynamics
mRAP [mmHg] 5 6
mPAP [mmHg] 30 71
PAWP [mmHg] 8 8
PVR [mmHg] 16.5 18
CO [L/min] 1.33 3.50
Clinical blood tests
Hb [g/l] 106
RDW [%] 17.6
WBC x10e9/l 2.7
Platelets x10e9/l 168
Creatinine [µmol/l] 129
BNP [ng/]l 171.8 220.0
ALP [IU/l] 92
Albumin [g/l] 40
ALT [IU/l] 26
AST [IU/l] 27
Bilirubin [µmol/l] 10
Total protein [g/l] 74
Cholesterol [mmol/l] 4.6
HDL [mmol/l] 1.16
LDL [mmol/l] 2.93
TG [mmol/l] 1.12
Lung function tests
FEV1 [% pred.] 82 67
FVC [% pred.] 82 65
FEV1/FVC 0.76  
KCO [% pred.] 92  
Comorbidities
 Systemic hypertension with LV hypertrophy, 
obstructive sleep apnoea, mild chronic kidney 
disease with renal cysts, cataract, benign 
prostatic enlargement
Diabetes mellitus type 2, 
systemic hypertension
Family history
Family members with PAH No No
eTable 4. Clinical phenotypes of BMP10 mutation carriers. 
WHO FC class – World Health Organization functional class; 6MWT – 6 minute walk test; mRAP – mean right 
atrial pressure; mPAP – mean pulmonary arterial pressure; PAWP - pulmonary artery wedge pressure; PVR –
pulmonary vascular resistance; CO – cardiac output; Hb – hemoglobin, RDW – red cell distribution width; 
WBC – white blood cell count; BNP - Brain Natriuretic Peptide; ALP - alkaline phosphatase; ALT – alanine 
aminotransferase; AST – aspartate aminotransferase; HDL - high density lipoprotein; LDL - low density 
lipoprotein; TG - triglycerides; FEV1 – forced expiratory volume; FVC – forced vital capacity; KCO – transfer 
coefficient for carbon monoxide.
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 [ALL]
N=380
Control
N=120
PAH
N=260
p-value N
Age at diagnosis 45 [34;59]  45 [34;59]  260
Age at sampling 52 [41;62] 51 [37;57] 53 [42;64] 0.019* 380
Diagnosis:     260
    HPAH 27 (10%)  27 (10%)   
    IPAH 233 (90%)  233 (90%)   
Case:     260
    incident 51 (20%)  51 (20%)   
    prevalent 209 (80%)  209 (80%)   
Gender: female 267 (70%) 77 (64%) 190 (73%) 0.100 380
BMI [kg/m2] 28 [24;32] 25 [24;30] 28 [24;32] 0.036 327
Ethnicity:    <0.001* 379
    White 293 (77%) 66 (55%) 227 (88%)   
    Asian 41 (11%) 22 (18%) 19 (7%)   
    Black 10 (3%) 6 (5%) 4 (2%)   
    Caribbean 1 (0%) 0 (0%) 1 (0%)   
    Other 30 (8%) 24 (20%) 6 (2%)   
    Not stated 4 (1%) 2 (2%) 2 (1%)   
Smoking history:    <0.001* 354
    no 205 (58%) 88 (86%) 117 (46%)   
    past/current 149 (42%) 14 (14%) 135 (54%)   
Systemic hypertension 74 (20%) 20 (20%) 54 (21%) 0.919 362
Coronary artery disease 15 (4%) 7 (7%) 8 (3%) 0.140 362
Diabetes mellitus type 2 42 (12%) 3 (3%) 39 (15%) 0.002* 362
Dyslipidemia 31 (9%) 9 (9%) 22 (8%) 1.000 362
Hypothyroidism 42 (12%) 4 (4%) 38 (15%) 0.007* 362
Obstructive sleep apnoea 12 (3%) 0 (0%) 12 (5%) 0.023* 362
  
eTable 5. Clinical characteristics of patients and controls in whom BMP9 and pBMP10 measurements 
were undertaken. Data presented as: count (%), median [IQR], BMI – body mass index; there was no diagnosis 
of Hereditary Hemorrhagic Telangiectasia in the entire cohort. *significant after multiple testing correction by 
Benjamini & Hochberg (11).
Page 52 of 72 AJRCCM Articles in Press. Published on 29-October-2019 as 10.1164/rccm.201906-1141OC 
 Copyright © 2019 by the American Thoracic Society 
16
Distribution across quartiles for combined control and PAH BMP9 values
0-25 25-50 50-75 75-100
BMP9 Males C= 7/43 (16%)
P= 21/70 (30%)
C= 14/43 (33%)
P= 15/70 (21%)
C= 10/43 (23%)
P= 18/70 (26%)
C= 12/43 (28%)
P= 16/70 (23%)
BMP9 Females C= 11/77 (14%)
P= 56/190 (29%)
C= 26/77 (34%)
P= 39/190 (21%)
C= 19/77 (23%)
P= 46/190 (24%)
C= 21/77 (28%)
P= 49/190 (26%)
Distribution across quartiles for combined control and PAH pBMP10 values
0-25 25-50 50-75 75-100
pBMP10 Males C= 7/43 (16%)
P= 20/67 (30%)
C= 12/43 (28%)
P= 15/70 (22%)
C= 12/43 (28%)
P= 16/70 (24%)
C= 11/43 (26%)
P= 16/70 (24%)
pBMP10 
Females
C= 10/77 (13%)
P= 56/187 (30%)
C= 20/77 (26%)
P= 46/187 (25%)
C= 24/77 (31%)
P= 42/187 (22%)
C= 23/77 (30%)
P= 43/187 (23%)
eTable 6. PAH patients are overrepresented in the lowest 25% of plasma BMP9 and pBMP10 
measurements for males and females. For BMP9, the values for controls (C) and PAH patients (P) were 
pooled for males and analysed. The median and 25% and 75% boundaries were determined for all the data 
values. The number of controls and PAH patients in each quartile were counted. The number of male controls in 
each quartile was expressed as a percentage of the total number of male control samples. Accordingly, the 
number of male PAH patients was expressed as the percentage of the total number of male PAH samples. The 
same approach was then applied to BMP9 levels in females and pBMP10 levels in males and in females. In all 
cases, the proportion of PAH patients falling in the 0-25% cluster was approximately double the percentage of 
controls falling in this quartile.
The proportion of individuals having both BMP9 and pBMP10 levels in their lowest quartile were 1/7 
(14%) control males and 8/77 (10%) control females. In contrast, a higher proportion of PAH patients with both 
BMP9 and pBMP10 levels in the lowest quartile were represented for males (14/21 (67%) for BMP9 and 14/20 
(70%) for pBMP10) and females (38/56 (68%) for BMP9 and pBMP10).
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 [ALL]N=260
Lower tertile
N=94
Middle tertile
N=80
Higher tertile
N=86 p-overall* N
Demographics and functional status
Age at sampling 53 [42;64] 54 [42;67] 49 [41;63] 56 [44;64] 0.261 260
Gender: female 190 (73%) 57 (61%) 60 (75%) 73 (85%) 0.001 260
BMI [kg/m2] 27 [24;32] 28 [25;32] 27 [24;31] 27 [22;31] 0.263 174
WHO class:     0.178 258
    1 31 (12%) 6 (6%) 13 (16%) 12 (14%)   
    2 99 (38%) 39 (41%) 29 (37%) 31 (36%)   
    3 115 (45%) 46 (49%) 30 (38%) 39 (46%)   
    4 13 (5%) 3 (3%) 7 (9%) 3 (4%)   
6MWD [m] 389 [335;452] 394 [366;428] 370 [288;481] 390 [336;435] 0.772 116
Shuttle walk test [m] 375 [304;515] 418 [312;625] 330 [275;431] 388 [341;460] 0.558 30
Hemodynamics
mRAP [mmHg] 10 [4;12] 9 [5;13] 8 [4;12] 11 [8;12] 0.326 38
mPAP [mmHg] 49 [39;63] 47 [32;50] 42 [36;58] 59 [42;66] 0.158 39
PVR [WU] 8.05 [5.72;13.9] 8.05 [6.45;12.8] 7.40 [4.00;10.9] 10.4 [6.20;17.4] 0.430 36
CO [L/min] 4.7 (2.1) 4.6 (2.3) 5.3 (2.0) 4.1 (2.0) 0.289 38
Lung function
FEV1 [% pred.] 86 (20) 87 (21) 83 (19) 88 (19) 0.763 58
FVC [ % pred.] 99 (21) 97 (21) 99 (23) 99 (20) 0.950 59
KCO [% pred.] 77 (16) 81 (14) 67 (17) 82 (11) 0.016 36
Clinical blood tests
Hb [g/l] 141 [130;152] 146 [128;157] 141 [133;152] 139 [128;148] 0.148 239
RDW [%] 14 [14;16] 15 [14;16] 14 [14;16] 14 [14;15] 0.007 173
WBC [x10e9/l] 7.0 [5.5;8.6] 7.3 [6.0;9.1] 7.0 [5.3;8.3] 6.5 [5.3;8.4] 0.083 240
Plt [x10e9/l] 212 [170;259] 188 [158;238] 221 [179;264] 224 [175;271] 0.016 240
Albumin [g/l] 42 [39;45] 42 [38;44] 43 [40;46] 42 [39;45] 0.072 249
ALP [IU/l] 79 [62,101] 84 [62;118] 76 [61;88] 81 [63;99] 0.222 247
ALT [IU/l] 21 [16;27] 20 [15;28] 22 [16;29] 21 [16;26] 0.532 248
AST [IU/l] 24 [19;28] 22 [18;28] 23 [19;28] 24 [20;28] 0.585 181
Bilirubin [µmol/l] 10 [8;14] 11 [8;16] 9 [8;14] 9 [7;13] 0.069 249
CRP [mg/l] 2 [1;6] 5 [2;11] 2 [1;5] 2 [1;3] 0.001 174
Total protein [g/l] 72 [68;75] 71 [66;76] 72 [68;74] 71 [69;74] 0.925 189
Sodium [mmol/l] 140 [139;141] 140 [138;141] 140 [139;142] 140 [139;142] 0.841 244
Potassium [mmol/l] 4.1 (0.4) 4.2 (0.5) 4.1 (0.4) 4.1 (0.4) 0.198 244
Urea [mmol/l] 5.6 [4.2;6.9] 5.9 [4.5;7.5] 5.5 [4.2;6.5] 5.6 [4.1;6.7] 0.123 244
Creatinine [mmol/l] 79 [68;97] 82 [69;102] 81 [68;98] 76 [66;91] 0.111 242
NTproBNP [ng/l] 222 [61.5;1230] 538 [81.0;1836] 151 [53.3;382] 176 [57.5;1126] 0.031 110
BNP [ng/l] 64.8 [30.1;167] 72.4 [29.0;147] 51.6 [28.5;200] 82.0 [36.7;146] 0.993 101
Comorbidities
HTN 54 (21%) 24 (26%) 18 (22%) 12 (14%) 0.144 260
DM type 1 5 (2%) 2 (2%) 1 (1%) 2 (2%) 1.000 260
DM type 2 39 (15%) 14 (15%) 15 (19%) 10 (12%) 0.438 260
CAD 8 (3%) 3 (3%) 3 (4%) 2 (2%) 0.907 260
CVA 4 (2%) 3 (3%) 1 (1%) 0 (0%) 0.269 260
Dyslipidemia 22 (8%) 5 (5%) 12 (15%) 5 (6%) 0.041 260
AVM 2 (1%) 1 (1%) 1 (1%) 0 (0%) 0.760 260
Epistaxis 3 (1%) 1 (1%) 1 (1%) 1 (1%) 1.000 260
Hepatitis 4 (2%) 2 (2%) 1 (1%) 1 (1%) 1.000 260
Hypothyroidism 38 (15%) 16 (17%) 11 (14%) 11 (13%) 0.700 260
COPD 10 (4%) 6 (6%) 1 (1%) 3 (3%) 0.258 260
Asthma 28 (11%) 9 (10%) 9 (11%) 10 (12%) 0.894 260
OSA 12 (5%) 7 (7%) 4 (5%) 1 (1%) 0.112 260
Heterotaxia 1 (0%) 1 (1%) 0 (0%) 0 (0%) 1.000 260
Asplenia 1 (0%) 1 (1%) 0 (0%) 0 (0%) 1.000 260
Cancer 17 (7%) 6 (6%) 6 (8%) 5 (6%) 0.905 260
eTable 7. Clinical characteristics at the time of sampling of I/HPAH cases by BMP9 concentration 
tertiles. Tertiles’ ranges: lower 0 – 186.7 pg/ml, middle 189.6 – 266.7 pg/ml, 267.1 – 591.2 pg/ml. Data 
presented as: † median [interquartile range], ^count (%), ‡ mean (SD), IPAH – idiopathic pulmonary arterial 
hypertension; HPAH – hereditary pulmonary arterial hypertension (diagnosis based on positive family history); 
BMI – body mass index; WHO class – World Health Organization functional class; 6MWT – 6 minute walk 
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test; mRAP – mean right atrial pressure; mPAP – mean pulmonary arterial pressure; PVR –pulmonary vascular 
resistance; CO – cardiac output; FEV1 – forced expiratory volume; FVC – forced vital capacity; KCO – transfer 
coefficient for carbon monoxide; NO challenge – nitric oxide challenge; Hb – hemoglobin, RDW – red cell 
distribution width; WBC – white blood cell count; Plt – platelets; ALP – alkaline phosphatase; ALT – alanine 
aminotransferase; AST – aspartate aminotransferase; AVM - arteriovenous malformation (one hepatic AVM 
and one pulmonary AVM); CRP – C-reactive protein; DM type 1 - Diabetes mellitus type 1; DM type 2 - 
diabetes mellitus type 2; OSA - obstructive sleep apnoea; CAD - coronary artery disease; CVA - cardiovascular 
accident; HTN – systemic hypertension. *None of the comparisons remained significant after adjustment for 
multiple comparisons by Benjamini & Hochberg (11).
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 [ALL]N=254
Lower tertile
N=99
Middle tertile
N=76
Higher tertile
N=79 p-overall* N
Demographics and functional status
Age at sampling 53 [42;64] 55 [43;67] 52 [40;63] 51 [42;61] 0.243 254
Gender: female 187 (74%) 66 (67%) 56 (74%) 65 (82%) 0.063 254
BMI [kg/m2] 27 [24;32] 30 [26;33] 27 [24;31] 26 [21;29] 0.004 170
WHO class:     0.005 252
    1 31 (12%) 3 (3%) 13 (17%) 15 (19%)   
    2 96 (38%) 38 (39%) 29 (38%) 29 (37%)   
    3 112 (44%) 53 (54%) 28 (37%) 31 (40%)   
    4 13 (5%) 4 (4%) 6 (8%) 3 (4%)   
6MWD [m] 390 [335;460] 385 [308;420] 380 [315;481] 415 [370;462] 0.305 113
Shuttle walk test [m] 370 [300;500] 340 [300;520] 380 [320;500] 370 [332;436] 0.867 29
Hemodynamics
mRAP[mmHg] 10 [4;12] 9 [7;13] 12 [4;12] 9 [5;11] 0.900 38
mPAP[mmHg] 49 [39;63] 40 [38;49] 48 [36;60] 60 [44;65] 0.186 39
PVR [WU] 8.05 [5.72;13.9] 6.10 [3.25;10.7] 7.70 [5.78;10.1] 11.8 [6.80;17.4] 0.138 36
CO[L/min] 4.7 (2.1) 4.5 (2.3) 5.4 (2.2) 4.1 (1.8) 0.315 38
Lung function
FEV1[% pred.] 86 (20) 83 (18) 88 (21) 86 (21) 0.720 56
FVC[% pred.] 99 (21) 92 (19) 105 (23) 99 (21) 0.194 57
KCO[% pred.] 76 (15) 74 (19) 71 (16) 81 (11) 0.233 35
Clinical blood tests
Hb [g/l] 140 [129;152] 140 [122;154] 141 [132;152] 140 [130;150] 0.802 233
RDW [%] 14 [14;15] 15 [14;16] 14 [14;16] 14 [13;15] 0.004 168
WBC [x10e9/l] 7.0 [5.5;8.6] 7.4 [5.8;9.0] 7.0 [5.8;8.3] 6.5 [5.1;8.1] 0.041 234
Plt [x10e9/l] 212 [170;260] 196 [161;262] 231 [175;270] 203 [170;246] 0.151 234
Albumin [g/l] 42 [39;45] 41 [37;45] 42 [40;46] 43 [40;46] 0.017 243
ALP [IU/l] 79 [62;101] 85 [66;111] 69 [57;88] 82 [62;100] 0.004 241
ALT [IU/l] 21 [16;27] 21 [16;29] 20 [15;24] 22 [17;28] 0.191 242
AST [IU/l] 23 [19;28] 23 [19;28] 22 [19;26] 24 [20;31] 0.158 177
Bilirubin [µmol/l] 10 [8;14] 10 [8;14] 9 [8;14] 10 [7;14] 0.750 243
CRP [mg/l] 2 [1;6] 4 [2;10] 2 [1;4] 2 [1;3] 0.001 171
Total protein [g/l] 72 [68;75] 72 [67;75] 72 [68;75] 71 [68;74] 0.729 185
Sodium [mmol/l] 140 [139;141] 140 [138;141] 140 [139;142] 140 [139;142] 0.251 238
Potassium [mmol/l] 4.1 (0.4) 4.2 (0.5) 4.1 (0.4) 4.1 (0.4) 0.373 238
Urea [mmol/l] 5.6 [4.2;7.0] 5.8 [4.2;7.5] 5.6 [4.5;6.5] 5.2 [4.0;6.5] 0.179 238
Creatinine [mmol/l] 80 [68;96] 82 [69;100] 79 [68;96] 77 [67;91] 0.181 236
NTproBNP [ng/l] 223 [61.5;1230] 332 [75.7;1849] 167 [59.0;984] 191 [60.0;839] 0.242 106
BNP [ng/l] 61.7 [30.1;148] 59.2 [28.8;143] 93.2 [39.9;156] 58.8 [30.5;169] 0.808 99
Comorbidities
HTN 53 (21%) 29 (29%) 16 (21%) 8 (10%) 0.008 254
DM type 1 5 (2%) 2 (2%) 1 (1%) 2 (3%) 1.000 254
DM type 2 38 (15%) 22 (22%) 11 (14%) 5 (6%) 0.013 254
CAD 7 (3%) 3 (3%) 4 (5%) 0 (0%) 0.106 254
CVA 4 (2%) 2 (2%) 2 (3%) 0 (0%) 0.471 254
Dyslipidemia 21 (8%) 5 (5%) 9 (12%) 7 (9%) 0.263 254
AVM 2 (1%) 1 (1%) 1 (1%) 0 (0%) 0.757 254
Epistaxis 3 (1%) 1 (1%) 1 (1%) 1 (1%) 1.000 254
Hepatitis 4 (2%) 3 (3%) 1 (1%) 0 (0%) 0.317 254
Hypothyroidism 37 (15%) 16 (16%) 12 (16%) 9 (11%) 0.627 254
COPD 8 (3%) 5 (5%) 3 (4%) 0 (0%) 0.101 254
Asthma 27 (11%) 10 (10%) 7 (9%) 10 (13%) 0.766 254
OSA 11 (4%) 8 (8%) 2 (3%) 1 (1%) 0.086 254
Heterotaxia 1 (0%) 1 (1%) 0 (0%) 0 (0%) 1.000 254
Asplenia 1 (0%) 1 (1%) 0 (0%) 0 (0%) 1.000 254
Cancer 16 (6%) 7 (7%) 5 (7%) 4 (5%) 0.899 254
 eTable 8. Clinical characteristics at the time of sampling of I/HPAH cases by pBMP10 concentration 
tertiles. Tertiles’ ranges: lower 0 – 5105  pg/ml, middle 5151 – 7699 pg/ml, 7702 – 17806 pg/ml. Data 
presented as: † median [interquartile range], ^count (%), ‡ mean (SD),  IPAH – idiopathic pulmonary arterial 
hypertension; HPAH – hereditary pulmonary arterial hypertension (diagnosis based on positive family history); 
BMI – body mass index; WHO FC class – World Health Organization functional class; 6MWD – 6 minute walk 
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distance;  mRAP – mean right atrial pressure; mPAP – mean pulmonary arterial pressure; PVR – pulmonary 
vascular resistance; CO – cardiac output; FEV1 – forced expiratory volume; FVC – forced vital capacity; KCO 
– transfer coefficient for carbon monoxide; NO challenge – nitric oxide challenge; Hb – hemoglobin, RDW – 
red cell distribution width; WBC – white blood cell count; Plt – platelets; ALP – alkaline phosphatase; AST – 
aspartate aminotransferase; ALT – alanine aminotransferase; AVM - arteriovenous malformation (one hepatic 
AVM and one pulmonary AVM); DM type 1 - Diabetes mellitus type 1; DM type 2 - diabetes mellitus type 2; 
OSA - obstructive sleep apnoea; CAD - coronary artery disease; CVA - cardiovascular accident; HTN - 
systemic hypertension; *None of the comparisons remained significant after adjustment for multiple 
comparisons by Benjamini & Hochberg (11).
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1eFigure 1: Mutations in BMP9 (a) Large scale deletions leading to loss of the GDF2 allele and surrounding genes in two patients with PAH. The region of Chromosome 10 
that is deleted is indicated by a box. The turquoise boxes show the coverage of the two deletions and the red vertical line indicates the position of the GDF2 gene, encoding 
BMP9. (b) Mapping of the position of Tyrosine-351 on the BMP9 structure (Magenta). This Tyrosine forms a hydrogen bond with Methionine-421, an interaction which will 
be disrupted by the amino acid substitution in the Y351H mutant and may lead to destabilisation of the GFD due to disruption of the hydrophobic core. (c) Familial clustering 
of the PAH phenotype with the Adenine-to-Guanosine Mutation at Position 265 of the GDF2 gene leading to the M89V Missense Mutation in BMP9. The arrow indicates the 
proband. Whole genome sequencing data was only available for the proband. 
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1eFigure 2: Efficiency curves for the ELISA analysis of each BMP9 mutant variant. Concentration curves of 
the BMP9 mutants were analysed by ELISA and the BMP9 GFD concentrations determined. Plotting of the 
calculated BMP9 GFD dilutions against the absorbances confirmed that the BMP9 mutant curves superimposed 
on the BMP9-WT curve, indicating that the efficiencies of binding in the ELISA were equivalent. n = number of 
points fitted for each sample.  
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2eFigure 3: Altered glycosylation of the BMP9-D218N variant and impaired furin processing of the BMP9-
S320C mutant. (a) Comparison of the partial protein sequences indicating the position of the S320C missense 
mutation (Substituted C in bold) adjacent to the consensus RRKR furin cleavage motif in the ProBMP9 
precursor. (b) Western blotting of cell lysates and conditioned media from HEK-EBNA cells exogenously 
expressing BMP9-wt and BMP9-S320C were analysed by Western blotting. The GFD was analysed by reducing 
SDS-PAGE (right panel) and prodomain analysed by under both reducing conditions (in cells and conditioned 
media) and non-reducing conditions (conditioned media). The numbered arrows indicate the nature of the 
processed forms as defined in Figure 1a. (c) In silico prediction of the glycosylation of the BMP9-D218N 
variant, showing the two consensus glycosylation sites (Black) at Arginine-71 (N71) and Arginine-176 (N176) 
and the predicted de novo site introduced by the change from Aspartic acid to Arginine at position 218. (b-c) 
The media from HEK-EBNA cells exogenously expressing BMP9-WT and BMP9-D218N were subject to 
deglycosylation followed by Western blotting for (d) the BMP9 prodomain or (e) BMP9 GFD. All blots are 
representative of n=3 experiments.
Page 60 of 72 AJRCCM Articles in Press. Published on 29-October-2019 as 10.1164/rccm.201906-1141OC 
 Copyright © 2019 by the American Thoracic Society 
3eFigure 4: Dose response of C2C12 myoblasts transfected with or without hALK1. C2C12 mouse myoblast 
cells were transfected with BRE-firefly reporter and thymidine kinase-Renilla normalisation plasmids. A 
hALK1 expression vector was added to the transfection mix for some wells. Serum starved cells were treated 
with BMP9-WT for 6 hours before luminescence was determined.
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4eFigure 5: Titration of BMP9 variants against BMP9-WT. Dilutions of conditioned media containing 
BMP9-WT (a-d) or the BMP9 variants: (a) M89V, (b) Y351H and T413N), (c) A347V and (d) R110W and 
E143K, were analysed by western blotting. (e)  The relative amounts of each mutant were quantified by 
densitometry relative to the WT on the same blot to calculate relative expression values. Data are mean from 
n=3 blots for each variant.
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5eFigure 6: Validation of BMP9 GFD ELISA protocol for human plasma. All concentrations of BMPs in 
panels a-d are presented as GFD equivalents. (a) Cross-reactivity assessment showing the BMP9 ELISA detects 
the BMP9-GFD and Pro:BMP9 with equivalence, whereas BMP10-GFD and Pro:BMP10 do not cross-react. 
Data are representative of 3 separate experiments.  (b-d) The effect of Triton-X100 (0.5%) and EDTA (4.5mM) 
alone, or in combination, on the efficiency of Pro:BMP9 recovery (assay buffer supplemented to 0.2% goat 
serum (GS)) from plasma volumes of (b) 25µl, (c) 15µl and (d) 10µl. (e-g). The effect of Triton X-100 (0.5%) 
and EDTA (4.5mM) alone, or in combination, on the efficiency of Pro:BMP9 recovery (assay buffer 
supplemented to 0.2% goat serum (GS)) from plasma volumes of (e) 25µl, (f) 15µl and (g) 10µl. Data in b-g are 
mean of 3 separate experiments, each experiment using plasma from a different healthy male control. (h) 
Comparison of the measured levels of BMP9 in different volumes of plasma alone 5-100µl, or with 
supplementation with 0.5% Triton-X100 and 0.2% goat serum.  Immunoprecipitation of BMP9 confirmed that 
the ELISA was specifically detecting BMP9 in plasma. Data are mean ± SEM, n=4. Two-way ANOVA; 
*P<0.05, **P<0.01 ***P<0.001
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6eFigure 7: Confirmation of high affinity BMP9 responses in the HMEC1-BRE luciferase stable reporter 
line.  (a) Untransduced HMEC1 cells were treated with BMP9 (0.001-10ng/ml) in SFM for 1 hour or 4 hours 
and lysed for RNA. QPCR analysis of ID2 induction, normalized to B2M, was assessed. Data are mean ± SEM 
for n=3 experiments. (b) HMEC1-BRE cells were treated with BMP9 (0.003-3ng/ml) for 6 hours, followed by 
assay of luciferase activity. Data are representative of 3 separate experiments (n=4 wells/treatment).  
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7eFigure 8: Validation of pBMP10 ELISA protocol for human plasma. All concentrations of BMPs in panels 
a-d are presented as GFD equivalents. (a) Cross-reactivity assessment showing the pBMP10 ELISA detects 
Pro:BMP9, but not the BMP10 GFD, nor BMP9-GFD or Pro:BMP9. Data are representative of 3 separate 
experiments.  (b-d) The effect of Triton-X100 (0.5%) and EDTA (4.5mM) alone, or in combination, on the 
efficiency of Pro:BMP10 recovery (assay buffer supplemented to 0.2% goat serum (GS)) from plasma volumes 
of (b) 25µl, (c) 15µl and (d) 10µl. Data in b-g are mean of 3 separate experiments, each experiment using 
plasma from a different healthy male control.
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8eFigure 9: BMP9 and pBMP10 levels do not correlate with age for males or females in cases and controls. 
The levels of BMP9 and pBMP10 were assessed regarding any correlation to age for males or females using a 
Spearman test for (a-b) combined cases and controls, (c-d) cases only or (e-f) controls only.  
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9  
eFigure 10: Circulating BMP9 and pBMP10 are physically associated. (a) Endothelial cells were incubated 
with neat plasma from 4 different male donors or plasma from which BMP9 had been immunoprecipitated. 
After 8 hours, endothelial cell RNA was extracted and QPCR undertaken for ID1 and calculated as expression 
relative to B2M using the ΔΔCT method. (b) HMEC1-BRE cells quiesced in serum free media overnight were 
treated with 10% serum from 4 different male donors, from which BMP9 or BMP10 had been 
immunoprecipitated with the indicated reagents, for 6 hours before luciferase activity was assessed. (c) BMP9 
GFD and (d) pBMP10 concentration in EDTA-plasma immunoprecipitated with the indicated antibodies was 
assessed by ELISA Data are mean ± SEM; n=4, one-way ANOVA. Dotted lines represent basal activity of 
untreated cells.
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eFigure 11: The majority of plasma pBMP10 is unprocessed. All concentrations of BMPs in panels are 
presented as GFD equivalents. (a) Cross-reactivity assessment showing the pBMP10 ELISA detects Pro:BMP10 
and ProBMP10 (b) Cross-reactivity assessment showing the BMP10 GFD ELISA detects BMP10 GFD and 
Pro:BMP10 but not ProBMP10 (c) Pro:BMP10 was spiked into EDTA-plasma, and recovery efficiency was 
assessed compared to Pro:BMP10 spiked into ELISA diluent. The dotted horizontal lines represent the blank 
measurement. Data are representative of 3 separate experiments.  
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eFigure 12: BMP9 and pBMP10 levels negatively correlate with BMI in PAH cases, but not controls. The 
levels of BMP9 and pBMP10 were assessed regarding any correlation to BMI for males or females using a 
Spearman test for (a-b) cases or (c-d) controls.  
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eFigure 13: ROC curves for pBMP10 measurements as a predictor of systemic hypertension (HTN) and  
diabetes mellitus type 2 in I/HPAH patients.  ROC analysis for pBMP10 levels as a predictor of (a) systemic 
hypertension (HTN) and (b) diabetes mellitus type 2. The diagonal line indicates the line of no discrimination.
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eFigure 14. Kaplan-Meier survival curves for BMP9 and pBMP10 tertiles.
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